GW Pharmaceuticals plc announced the appointment of Kenneth Sommerville MD to the newly created position of VP, Clinical Science, based in the United States. Dr. Sommerville will play an important role in the clinical development, medical affairs, and regulatory activities related to the company's epilepsy programs including the ongoing development of Epidiolex(R), GW's product candidate for Dravet and Lennox-Gastaut syndromes. He will also support the late stages of the completion of the investigational plan for Sativex(R) in cancer pain.